IO Biotech, Inc.
IOBTNASDAQHealthcare
$0.01
$-0.00(-27.59%)
Market Cap$885690
P/E Ratio—
52W High$2.79
52W Low$0.01231
IO Biotech, Inc. (IOBT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
IOBT · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2025Report Date: Nov 14, 2025EPS Actual
-$0.28
Est. -$0.31 · +9.7%
Revenue
—
Fiscal Period
Q4 FY2025
FY ends December
Report Date
Nov 14, 2025
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
IOBT reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.02
Rev. $0.33B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.02
Rev. Est.$0.33B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2026 | May 13, 2026 | -$0.10 | — | — | — | — | — |
| ▲ Q4 FY2025 | Nov 14, 2025 | -$0.31 | -$0.28 | +9.7% | — | — | — |
| ▼ Q3 FY2025 | Aug 14, 2025 | -$0.35 | -$0.40 | -14.3% | — | — | — |
| ▲ Q2 FY2025 | May 14, 2025 | -$0.45 | -$0.34 | +24.4% | — | — | — |
| ▼ Q1 FY2025 | Mar 25, 2025 | -$0.38 | -$0.48 | -25.2% | — | — | — |
| ▼ Q4 FY2024 | Nov 12, 2024 | -$0.29 | -$0.36 | -24.1% | — | — | — |
| ▲ Q3 FY2024 | Aug 13, 2024 | -$0.34 | -$0.31 | +8.8% | — | — | — |
| ▲ Q2 FY2024 | May 14, 2024 | -$0.37 | -$0.30 | +18.9% | — | — | — |
Q2 FY2026
May 13, 2026
EPS Actual
—
EPS Est.
-$0.10
EPS Surpr.
—
Revenue
—
Q4 FY2025
Nov 14, 2025Beat
EPS Actual
-$0.28
EPS Est.
-$0.31
EPS Surpr.
+9.7%
Revenue
—
Q3 FY2025
Aug 14, 2025Miss
EPS Actual
-$0.40
EPS Est.
-$0.35
EPS Surpr.
-14.3%
Revenue
—
Q2 FY2025
May 14, 2025Beat
EPS Actual
-$0.34
EPS Est.
-$0.45
EPS Surpr.
+24.4%
Revenue
—
Q1 FY2025
Mar 25, 2025Miss
EPS Actual
-$0.48
EPS Est.
-$0.38
EPS Surpr.
-25.2%
Revenue
—
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
-$0.36
EPS Est.
-$0.29
EPS Surpr.
-24.1%
Revenue
—
Q3 FY2024
Aug 13, 2024Beat
EPS Actual
-$0.31
EPS Est.
-$0.34
EPS Surpr.
+8.8%
Revenue
—
Q2 FY2024
May 14, 2024Beat
EPS Actual
-$0.30
EPS Est.
-$0.37
EPS Surpr.
+18.9%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q3 FY2027 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q2 FY2027 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q1 FY2027 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q4 FY2026 | $-0.03 | $-0.03 | $-0.03 | 1 |
| Q3 FY2026 | $-0.04 | $-0.04 | $-0.04 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q4 FY2025 | Nov 14, 2025 | +9.7% | $0.81 | $0.83 | +1.71% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -14.3% | $1.31 | $1.28 | -2.29% |
| ▲ Q2 FY2025 | May 14, 2025 | +24.4% | $1.00 | $0.98 | -2.00% |
| ▼ Q1 FY2025 | Mar 25, 2025 | -25.2% | $1.00 | $1.17 | +17.00% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -24.1% | $1.05 | $0.93 | -11.68% |
| ▲ Q3 FY2024 | Aug 13, 2024 | +8.8% | $1.30 | $1.53 | +17.69% |
| ▲ Q2 FY2024 | May 14, 2024 | +18.9% | $1.41 | $1.44 | +2.13% |
| ▼ Q1 FY2024 | Mar 5, 2024 | -11.1% | $1.68 | $1.62 | -3.57% |
Q4 FY2025+1.71%
Report Date
Nov 14, 2025
EPS Beat/Miss
+9.7%
Price Before
$0.81
Price After
$0.83
Q3 FY2025-2.29%
Report Date
Aug 14, 2025
EPS Beat/Miss
-14.3%
Price Before
$1.31
Price After
$1.28
Q2 FY2025-2.00%
Report Date
May 14, 2025
EPS Beat/Miss
+24.4%
Price Before
$1.00
Price After
$0.98
Q1 FY2025+17.00%
Report Date
Mar 25, 2025
EPS Beat/Miss
-25.2%
Price Before
$1.00
Price After
$1.17
Q4 FY2024-11.68%
Report Date
Nov 12, 2024
EPS Beat/Miss
-24.1%
Price Before
$1.05
Price After
$0.93
Q3 FY2024+17.69%
Report Date
Aug 13, 2024
EPS Beat/Miss
+8.8%
Price Before
$1.30
Price After
$1.53
Q2 FY2024+2.13%
Report Date
May 14, 2024
EPS Beat/Miss
+18.9%
Price Before
$1.41
Price After
$1.44
Q1 FY2024-3.57%
Report Date
Mar 5, 2024
EPS Beat/Miss
-11.1%
Price Before
$1.68
Price After
$1.62
Avg Beat Reaction+4.88%
Avg Miss Reaction-0.13%
Beat Rate4 / 8 quarters
Largest Move+17.69% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: IOBT ends December
IO Biotech, Inc. (IOBT) most recently reported earnings on November 14, 2025 for Q4 FY2025, posting EPS of $-0.28 — beating the analyst consensus of $-0.31 by +9.7%. The next IOBT earnings date is expected around September 1, 2026.
Each quarter, investors track IOBT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. IOBT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
IOBT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
IOBT earnings · 5 questionsIO Biotech, Inc.'s next earnings report is expected around September 1, 2026. IOBT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; IOBT historically reports after market close (AMC).
IOBT earnings datewhen is IOBT earningsIOBT next earnings datewhen does IOBT report earningsIOBT earnings calendar
▸ Source: FMP · IO Biotech, Inc. SEC filings · US GAAP · IO Biotech, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026